Triple-negative Breast Cancer: New Perspectives for Targeted Therapies

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2015 Feb 6

PMID 25653541

Citations 68

Authors

Federica Tomao

Anselmo Papa

Eleonora Zaccarelli

Luigi Rossi

Davide Caruso

Marina Minozzi

Patrizia Vici

Luigi Frati

Silverio Tomao

Affiliations

Soon will be listed here.

Abstract

Breast cancer is a heterogeneous disease, encompassing a large number of entities showing different morphological features and having clinical behaviors. It has became apparent that this diversity may be justified by distinct patterns of genetic, epigenetic, and transcriptomic aberrations. The identification of gene-expression microarray-based characteristics has led to the identification of at least five breast cancer subgroups: luminal A, luminal B, normal breast-like, human epidermal growth factor receptor 2, and basal-like. Triple-negative breast cancer is a complex disease diagnosed by immunohistochemistry, and it is characterized by malignant cells not expressing estrogen receptors or progesterone receptors at all, and human epidermal growth factor receptor 2. Along with this knowledge, recent data show that triple-negative breast cancer has specific molecular features that could be possible targets for new biological targeted drugs. The aim of this article is to explore the use of new drugs in this particular setting, which is still associated with poor prognosis and high risk of distant recurrence and death.

Citing Articles

In vitro and in vivo activity of a novel oxamide-hydrazone hybrid derivative against triple-negative breast cancer.

Tahmasvand R, Dehghani S, Kooshafar Z, Emami Najafi S, Almasirad A, Salimi M Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(7):5119-5129.

PMID: 38240779 DOI: 10.1007/s00210-023-02931-6.

Cancer Cell Membrane Wrapped Nanoparticles for the Delivery of a Bcl-2 Inhibitor to Triple-Negative Breast Cancer.

Scully M, Wilkins D, Dang M, Hoover E, Aboeleneen S, Day E Mol Pharm. 2023; 20(8):3895-3913.

PMID: 37459272 PMC: 10628893. DOI: 10.1021/acs.molpharmaceut.3c00009.

Targeting and Sensitization of Breast Cancer Cells to Killing with a Novel Interleukin-13 Receptor α2-Specific Hybrid Cytolytic Peptide.

Jannoo R, Walker W, Kanamarlapudi V Cancers (Basel). 2023; 15(10).

PMID: 37345109 PMC: 10216279. DOI: 10.3390/cancers15102772.

BCL11A Expression in Breast Cancer.

Katnik E, Gomulkiewicz A, Piotrowska A, Grzegrzolka J, Rusak A, Kmiecik A Curr Issues Mol Biol. 2023; 45(4):2681-2698.

PMID: 37185699 PMC: 10137054. DOI: 10.3390/cimb45040175.

A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer.

Kumar H, Gupta N, Jain R, Madhunapantula S, Babu C, Kesharwani S J Adv Res. 2023; 54:271-292.

PMID: 36791960 PMC: 10703733. DOI: 10.1016/j.jare.2023.02.005.

References

Rao R, Balusu R, Fiskus W, Mudunuru U, Venkannagari S, Chauhan L . Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells. Mol Cancer Ther. 2012; 11(4):973-83. DOI: 10.1158/1535-7163.MCT-11-0979. View

Chang E, Frasor J, Komm B, Katzenellenbogen B . Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology. 2006; 147(10):4831-42. DOI: 10.1210/en.2006-0563. View

Pichot C, Hartig S, Xia L, Arvanitis C, Monisvais D, Lee F . Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer. 2009; 101(1):38-47. PMC: 2713704. DOI: 10.1038/sj.bjc.6605101. View

Barrott J, Cash G, Smith A, Barrow J, Murtaugh L . Deletion of mouse Porcn blocks Wnt ligand secretion and reveals an ectodermal etiology of human focal dermal hypoplasia/Goltz syndrome. Proc Natl Acad Sci U S A. 2011; 108(31):12752-7. PMC: 3150921. DOI: 10.1073/pnas.1006437108. View

Yunokawa M, Koizumi F, Kitamura Y, Katanasaka Y, Okamoto N, Kodaira M . Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. Cancer Sci. 2012; 103(9):1665-71. PMC: 7659327. DOI: 10.1111/j.1349-7006.2012.02359.x. View

Meric-Bernstam F, Gonzalez-Angulo A . Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009; 27(13):2278-87. PMC: 2738634. DOI: 10.1200/JCO.2008.20.0766. View

Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P . How basal are triple-negative breast cancers?. Int J Cancer. 2008; 123(1):236-40. DOI: 10.1002/ijc.23518. View

Maggiolini M, Vivacqua A, Fasanella G, Grazia Recchia A, Sisci D, Pezzi V . The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004; 279(26):27008-16. DOI: 10.1074/jbc.M403588200. View

Isola J . Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol. 1993; 170(1):31-5. DOI: 10.1002/path.1711700106. View

10.

Orlowski R, Baldwin Jr A . NF-kappaB as a therapeutic target in cancer. Trends Mol Med. 2002; 8(8):385-9. DOI: 10.1016/s1471-4914(02)02375-4. View

11.

Khan O, Gore M, Lorigan P, Stone J, Greystoke A, Burke W . A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer. 2011; 104(5):750-5. PMC: 3048218. DOI: 10.1038/bjc.2011.8. View

12.

Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales A . Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 2005; 123(1):21-7. DOI: 10.1309/4wv79n2ghj3x1841. View

13.

Lu C, Wyszomierski S, Tseng L, Sun M, Lan K, Neal C . Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res. 2007; 13(19):5883-8. DOI: 10.1158/1078-0432.CCR-06-2837. View

14.

Tseng L, Liu C, Chang K, Chu P, Shiau C, Chen K . CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res. 2012; 14(2):R68. PMC: 3446403. DOI: 10.1186/bcr3175. View

15.

Fukutomi A, Hatake K, Matsui K, Sakajiri S, Hirashima T, Tanii H . A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors. Invest New Drugs. 2011; 30(3):1096-106. DOI: 10.1007/s10637-011-9666-9. View

16.

Carey L, Rugo H, Marcom P, Mayer E, Esteva F, Ma C . TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012; 30(21):2615-23. PMC: 3413275. DOI: 10.1200/JCO.2010.34.5579. View

17.

Mita M, Joy A, Mita A, Sankhala K, Jou Y, Zhang D . Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. Clin Breast Cancer. 2014; 14(3):169-76. DOI: 10.1016/j.clbc.2013.10.016. View

18.

Bianchi G, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S . Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs. 2009; 20(7):616-24. View

19.

Filardo E, Quinn J, Bland K, Frackelton Jr A . Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol. 2000; 14(10):1649-60. DOI: 10.1210/mend.14.10.0532. View

20.

Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X . Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013; 14(10):933-42. DOI: 10.1016/S1470-2045(13)70335-8. View